One early success story is cystic fibrosis: since the gene was identified in 1989, exceptional progress has been made in devising new experimental treatments,
including gene therapy trials.
Not exact matches
There are now more than 100
gene therapy clinical
trials aimed toward cancer, genetic diseases (such as ADA deficiency, cystic fibrosis and hemophilia A), infectious diseases (
including AIDS) and autoimmune diseases (such as rheumatoid arthritis).
Women were not
included in the first
trial of
gene therapy, which was mainly concerned with proving the safety of the technique.
His story inspired a book, The Forever Fix, which heralded the LCA
trials as part of the wave of successes for
gene therapy, which was recovering from several setbacks —
including the death of a patient and cancer in others — in the late 1990s and early 2000s.
The current U.K.
trial is again using fats, or lipids, but the DNA
includes a segment called a promoter that should make
gene expression last longer, says Eric Alton of Imperial College London, who heads the UK Cystic Fibrosis Gene Therapy Consort
gene expression last longer, says Eric Alton of Imperial College London, who heads the UK Cystic Fibrosis
Gene Therapy Consort
Gene Therapy Consortium.
Other blood disorders that have shown significant benefit from targeted
gene therapy in small
trials include hemophilia (specifically, factor IX deficiency), severe beta - thalassemia (deficiency for the adult beta - globin
gene) and leukemia, where the patient's immune cells were treated to enable them to recognize cancer cells and destroy them.
The vector is a self - inactivating lentivirus — a member of a family of viruses that can insert
genes into mammalian cells and drive expression of those
genes — that has been engineered to avoid triggering the development of leukemia, a complication seen in previous
gene therapy trials for immunodeficiency syndromes,
including WAS.
Colleen Dansereau, RN, MSN, CPN Program Manager,
Gene Therapy Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (C
Gene Therapy Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease
Therapy Program As manager of the
Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (C
Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease
Therapy Program, Colleen administratively manages the CAR T - cell
therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease
therapy program as well as all administrative responsibility for all of the
gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (C
gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease
therapy clinical
trials that take place at Dana - Farber / Boston Children's, for conditions
including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (CGD).
Weill Cornell is the birthplace of many medical advances —
including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo - biopsy pregnancy and birth in the U.S., the first clinical
trial of
gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain - injured patient.
Dr. Azad is a national leader in GI cancer,
including serving as a member of the national NCI Colon Cancer Task Force and the NCI MATCH (Molecular Analysis for
Therapy Choice) Agents and
Genes Working Group, the largest
trial of personalized medicine in the country.
Dr. Jerry Mendell of Nationwide Children's Hospital recently joined us for a webinar to discuss his upcoming
gene therapy trial,
including trial design, inclusion / exclusion criteria, and timelines.
Lysogene's MPS IIIA
gene therapy clinical
trial strategy
includes a partnership with the MPS patient networks to ensure families are well informed about our development program and are able to make informed choices concerning the best treatment strategy for their children.
Treatment can
include surgery to excise the mesothelial and surrounding tissue, chemotherapy, drug regimens, drug
trials,
gene therapies, radiation, and draining of fluid followed by the injection of medication.
New treatments are being tested to tackle the crippling difficulties of vertigo,
including a clinical
trial of prosthetic ear implants and ear
gene therapy, with initial work revealing novel aspects of brain anatomy linked to balance which could be used as targets for future treatments.